Abstract
Precision medicine relies on molecular techniques to identify those patients with targetable molecular abnormalities. The finding of NTRK oncogene fusions could imply a therapeutic change in up to 25% of patients with radioiodine-refractory advanced differentiated thyroid tumors with criteria for initiation of systemic therapy. In this review, we propose a path of decisions based on the genomic interrogation approach in selected patient, at the appropriate time, with the available technologies, leading to the identification of those candidate to be treated with larotrectinib or entrectinib, the two tumor-agnostic drugs approved for this genetic alteration
